MAPT and Cognitive impairment: Positron emission tomography (PET) serves a pivotal tool for the in vivo visualisation and quantification of AD pathology [2], with tau-PET measuring tau pathological changes [3] that have been strongly associated with cognitive impairment and decline in AD.